Tirzepatide is another medication used to improve blood sugar control in adults. It has a greater affinity for GIP receptors than GLP-1 receptors, making it more effective in reducing hyperglycemia. Studies have shown that Tirzepatide can lead to an average weight loss of about 20% over 72 weeks. However, like semaglutide, it is limited to individuals with a BMI greater than 30 or a BMI greater than 27 with comorbid conditions unless working with Morph Health and Wellness where we are able to treat patients to a normal BMI.
The big takeaways:
- Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
- It works to improve blood sugar control by increasing insulin release.
- It has a greater affinity for glucose-dependent insulinotropic peptide (GIP) receptors.
- This makes it a great option for individuals with type 2 diabetes and obesity.
- Clinical trials have shown that it can lead to an average weight loss of about 20%.
If understanding Tirzepatide: A Second-Generation Medication is important; go deeper and learn more about GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication.
Help Center on GLP-1 and GIP Agonists: A Triple Ripple in Obesity Medication
A: Common side effects of semaglutide include nausea, diarrhea, vomiting, constipation, and abdominal pain.
A: Studies have shown an average weight loss of about 20% over 72 weeks with Tirzepatide.
A: Early data suggests a potential weight loss of 24% with Retatrutide.
A: Combining peptide therapy with these medications and optimizing testosterone levels can help prevent muscle loss.
A: Injection-based supplementation is recommended for optimizing vitamin D and B12 levels.
